Sort   by:  
 Page size 
UnknownThree-Year Outcomes With Hypofractionated Versus Conventionally Fractionated Whole-Breast Irradiation: Results of a Randomized, Noninferiority Clinical Trial.

Purpose

The adoption of hypofractionated whole-breast irradiation (HF-WBI) remains low, in part because of concerns regarding its safety when used with a tumor bed boost or in patients who have received chemotherapy or have large breast size. To address this, we conducted a randomized, multi...
S-EPMC6286164 | biostudies-literature
UnknownPhase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

Purpose

Trastuzumab resistance has been linked to activation of the phosphoinositol 3-kinase (PI3K) pathway. Phosphatase and tensin homolog (PTEN) is a dual phosphatase that counteracts the PI3K function; PTEN loss leads to activation of the Akt cascade and the downstream mammalian target of...
S-EPMC3157979 | biostudies-literature
UnknownCirculating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500.

Purpose

Increased circulating tumor cells (CTCs; five or more CTCs per 7.5 mL of whole blood) are associated with poor prognosis in metastatic breast cancer (MBC). A randomized trial of patients with persistent increase in CTCs tested whether changing chemotherapy after one cycle of first-li...
S-EPMC4209100 | biostudies-literature
UnknownSWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer.

Purpose

To determine the optimal dose and schedule of anthracycline and taxane administration as adjuvant therapy for early-stage breast cancer.

Patients and methods

A 2 × 2 factorial design was used to test two hypotheses: (1) that a novel continuous schedule of doxorubicin-cyclophos...
S-EPMC4268253 | biostudies-literature
UnknownCorrelative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.

Purpose

To explore the genetic landscape of tumors from patients enrolled on the BOLERO-2 trial to identify potential correlations between genetic alterations and efficacy of everolimus treatment. The BOLERO-2 trial has previously demonstrated that the addition of everolimus to exemestane pr...
S-EPMC5070556 | biostudies-literature
UnknownAdjuvant exemestane with ovarian suppression in premenopausal breast cancer.

Background

Adjuvant therapy with an aromatase inhibitor improves outcomes, as compared with tamoxifen, in postmenopausal women with hormone-receptor-positive breast cancer.

Methods

In two phase 3 trials, we randomly assigned premenopausal women with hormone-receptor-positive early bre...
S-EPMC4175521 | biostudies-literature
UnknownTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

Background

In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among...
S-EPMC6193457 | biostudies-literature
UnknownAdjuvant ovarian suppression in premenopausal breast cancer.

Background

Suppression of ovarian estrogen production reduces the recurrence of hormone-receptor-positive early breast cancer in premenopausal women, but its value when added to tamoxifen is uncertain.

Methods

We randomly assigned 3066 premenopausal women, stratified according to prio...
S-EPMC4341825 | biostudies-literature
Sort   by:  
 Page size